Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis

Hepatology

Volumn 53, Issue 3, 2011, Pages 926-934

  Yeoman, Andrew D ^a   Westbrook, Rachel H ^a   Zen, Yoh ^a   Maninchedda, Paola ^a   Portmann, Bernard C ^a   Devlin, John ^a   O'Grady, John G ^a   Harrison, Phillip M ^a   Heneghan, Michael A ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CREATININE; GLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SODIUM; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG TREATMENT FAILURE; EMERGENCY SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMAPHERESIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPSIS; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; CHILD; END STAGE LIVER DISEASE; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; JAUNDICE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 79952203791     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24141     Document Type: Article

References (44)

1. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. HEPATOLOGY 2002; 35: 7-13.
2. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95: 448-453.
3. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994; 21: 866-871.
4. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997; 27: 578-582.
5. Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998; 17: 297-300.
6. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2: 625-631.
7. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833.
8. Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976; 8: 221-227.
9. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.
10. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. HEPATOLOGY 2000; 31: 864-871.
11. Chan HLY CA, Lau JTF, Hui AY, Wong VWS, Sung JJY. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 2006; 101: 1516-1523.
12. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700-706.
13. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KVN, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. HEPATOLOGY 2005; 41: 353-358.
14. Chalasani N, Kahi C, Francois F, Pinto AO, Marathe A, Bini EJ, et al. Model for end-stage liver disease (MELD for predicting mortality in patients with acute variceal bleeding. HEPATOLOGY 2002; 35: 1282-1284.
15. Wehler M, Koskoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. HEPATOLOGY 2001; 34: 255-261.
16. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. HEPATOLOGY 2007; 46: 1138-1145.
17. Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation andallocation of donated livers in the UK. GUT 2008; 57: 252-257.
18. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45: 575-583.
19. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185.
20. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-737.
21. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. HEPATOLOGY 1997; 25: 541-547.
22. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999; 30: 394-401.
23. Villamil AG, Casciato P, Eduardo M, Bustos D, Giunta D, Ciardullo M, et al. Fulminant autoimmune hepatitis: clinical presentation, outcome and prognostic factors. Am J Transpl 2005; 5(Suppl 11): 278.
24. Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol 1994; 7: 690-713.
25. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.
26. Al-Chalabi T, Underhill J, Portmann BC, McFarlane IG, Heneghan MA. Effects of serum aspartate transaminase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 2008; 6: 1389-1395.
27. Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. HEPATOLOGY 2003; 38: 1363-1369.
28. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-1516.
29. Lotz G, Koltai P, Schaff Z. Giant cell hepatitis in adults. Pathol Oncol Res 1997; 3: 215-218.
30. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. HEPATOLOGY 1992; 15: 572-577.
31. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003; 25: 263-270.
32. Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006; 23: 1347-1353.
33. Ichai P, Duclos-Vallee J-C, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transplant 2007; 13: 996-1003.
34. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SHB. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
35. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993; 104: 1755-1761.
36. Bernal W, Ma Y, Smith HM, Portmann B, Wendon J, Vergani D. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol 2007; 47: 664-670.
37. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-963.
38. Stellon AJ, Hegarty JE, Portmann B, Williams R. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985; 1: 668-670.
39. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. HEPATOLOGY 1988; 8: 781-784.
40. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 1036-1040.
41. Hennes EM, Oo Y, Schramm C, Denzer U, Buggisch P, Wiegard Cea. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-3070.
42. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Hansen BA. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-3236.
43. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-809.
44. Heneghan MA, Rizzi P, McFarlane IG, Portmann B, Harrison PM. Low dose tacrolimus as treatment of severe autoimmune hepatitis: potential role in remission induction. Gut 1999; 44: A61.